Pizzini A, Bacher H, Aichner M, et al. - This study was undertaken to investigate whether high expression of mTOR signaling in granulomatous lesions is not predictive for the clinical course of sarcoidosis. Researchers conducted a retrospective analysis including a total of 58 patients with histologically confirmed sarcoidosis. They assessed immunohistochemical staining of granulomas from tissue samples for the expression of activated mechanistic target of Rapamycin complex 1 (mTORC1) signaling, including phosphorylated mTOR, its downstream effectors S6K1, 4EBP1and the proliferation marker Ki-67. Individuals were classified according to different clinical phenotypes, serum biomarkers, and immunomodulatory therapy. The results exhibited that the activation of the mTORC1 pathway in sarcoidosis, supporting the hypothesis that mTOR is a significant driver in granuloma formation. Nevertheless, they did not observe an association between the degree of mTOR activation and disease severity or the need for therapy.